Eng
Address: 2 Lenina Street, Loyev, Gomel Oblast, the Republic of Belarus, 247095
Phone: +375 2347 2 04 10
E-mail: isp@loev.gov.by
Republic
MINSK, 26 March (BelTA) – The Sputnik V vaccine produced in Belarus will undergo quality control at the Gamaleya National Research Institute of Epidemiology and Microbiology of Russia's Ministry of Health, Belmedpreparaty Director General Sergei Belyayev told reporters, BelTA has learned.
The Belmedpreparaty pharmaceutical company started mass production of the Russian vaccine Sputnik V.
“Quality control of this vaccine will be in progress in the next three weeks. The vaccine will undergo comprehensive quality control to check its quality and safety,” Sergei Belyayev said. He added that the quality control will be done at the Galaleya center where the vaccine was developed.
Sergei Belyayev noted that the first validation batches of the Sputnik V vaccine produced at Belmedpreparaty also passed the necessary laboratory tests. “The product proved to be completely identical to the original one across all quality indicators,” he added.
The vaccine will be available for mass vaccination starting from late April, after quality control findings are received. The first batch will be as big as up to 100,000 doses. After that up to 500,000 doses will be made every month.
26.03.2021
Sputnik V vaccine produced in Belarus to undergo quality control at Gamaleya center
MINSK, 26 March (BelTA) – The Sputnik V vaccine produced in Belarus will undergo quality control at the Gamaleya National Research Institute of Epidemiology and Microbiology of Russia's Ministry of Health, Belmedpreparaty Director General Sergei Belyayev told reporters, BelTA has learned.
The Belmedpreparaty pharmaceutical company started mass production of the Russian vaccine Sputnik V.
“Quality control of this vaccine will be in progress in the next three weeks. The vaccine will undergo comprehensive quality control to check its quality and safety,” Sergei Belyayev said. He added that the quality control will be done at the Galaleya center where the vaccine was developed.
Sergei Belyayev noted that the first validation batches of the Sputnik V vaccine produced at Belmedpreparaty also passed the necessary laboratory tests. “The product proved to be completely identical to the original one across all quality indicators,” he added.
The vaccine will be available for mass vaccination starting from late April, after quality control findings are received. The first batch will be as big as up to 100,000 doses. After that up to 500,000 doses will be made every month.